------ =_NextPart_000_01BC84D7.589005C0
Content-Type: text/plain; charset="us-ascii"
Content-Transfer-Encoding: 7bit
-----Original Message-----
From: Joe Bruman [SMTP:[log in to unmask]]
Sent: Sunday, June 29, 1997 6:16 AM
To: Multiple recipients of list PARKINSN
Subject: CSRINDX JUL 97
I N D E X , C U R R E N T S C I E N C E R E V I E W S
I've never done this before, so please walk me thru the process.
I would like information on Permax and I see the following articles
on such:
Agonists, action May 95 Neur 1995;45S3:S5
Pergolide (Permax) May 95 Neur 1995;45S3:S5
" May 95 Neur 1995;45S3:S13-S21
" May 95 Neur 1995;45S3:S22-S27
thanks, Mark Hardy
[log in to unmask]
------ =_NextPart_000_01BC84D7.589005C0
Content-Type: application/ms-tnef
Content-Transfer-Encoding: base64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------ =_NextPart_000_01BC84D7.589005C0--
